X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMC-2 (combination of valacyclovir and celecoxib) is being evaluated in phase 2 clinical trials as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
IMC-2 (combination of valacyclovir + celecoxib) is being evaluated in phase 2 clinical trials as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or Long Covid.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
The Company has initiated the 10-day termination process under the Sales Agreement and is focusing its attention on short-to-medium term operational priorities, including assessment of IMC-2 (fixed combination of valacyclovir and celecoxib) in Long-COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 18, 2023
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
IMC-1 (Famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 22, 2022
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
